

Daclatasvir + sofosbuvir
Essential medicine status
General description

INN
Daclatasvir + sofosbuvir
ATC codes
[J05AP07](#) [J05AP08](#)
Medicine type
Chemical agent
EML status history
First added in 2021 ([TRS 1035](#)) for [Chronic hepatitis C](#)
Wikipedia
[Daclatasvir + sofosbuvir](#)
DrugBank
[Daclatasvir](#) ,
[Sofosbuvir](#)
Recommendations
Section
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

- Oral > Solid > tablet: 60 mg (as dihydrochloride) + 400 mg

Indications
[Chronic hepatitis C](#)